The United States Preventive Services Task Force (USPSTF), an independent volunteer panel of national experts in disease prevention and evidence-based medicine, has released a recommendation that all people with an increased risk of acquiring HIV take pre-exposure prophylaxis, aka PrEP, to protect them from infection. USPSTF wants to improve the health of all Americans with evidence-based recommendations about preventive services that should be employed. They also highlight any areas of uncertainty where additional research is needed to strengthen recommendations. The Task Force releases a draft of their recommendations to allow for a period of public comment before making a final recommendation. The PrEP recommendation released on Nov 20, 2018 was open for comment until Dec 26, 2018. The final recommendation was released in early 2019, along with a comprehensive review of the evidence used to make the recommendation.
Endorsing existing guidelines by the US Public Health Service and the World Health Organization, all people at increased risk of HIV should be offered PrEP as part of a comprehensive prevention plan. People with increased risk are defined as; men who have sex with men, people who inject drugs, and others at risk via hetrosexual contact. Only about 7% of people considered “at risk” of HIV acquisition are taking PrEP. Truvada is the only medication approved by the FDA for PrEP.
USPSTF recommendations generally do not have any official standing, but they are often used by professional societies and insurers to develop guidelines for medical providers, and are often incorporated into a “standard of care” by the medical community.
To view the draft guidelines, see https://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/prevention-of-human-immunodeficiency-virus-hiv-infection-pre-exposure-prophylaxis